CARsgen Therapeutics Holdings Limited (HKG:2171)
12.56
-0.87 (-6.48%)
Sep 10, 2026, 11:59 AM HKT
CARsgen Therapeutics Holdings Employees
CARsgen Therapeutics Holdings had 424 employees as of June 30, 2026. The number of employees increased by 69 or 19.44% since the number was reported on December 31, 2025.
Employees
424
Change
69
Growth
19.44%
Revenue / Employee
371.99K HKD
Profits / Employee
-242.83K HKD
Market Cap
7.55B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Jun 30, 2026 | 424 | 69 | 19.44% | 424 | 0 |
| Dec 31, 2025 | 355 | -110 | -23.66% | 355 | 0 |
| Dec 31, 2024 | 465 | -51 | -9.88% | 465 | 0 |
| Dec 31, 2023 | 516 | -31 | -5.67% | 516 | 0 |
| Dec 31, 2022 | 547 | -26 | -4.54% | 539 | 8 |
| Dec 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Shanghai Haohai Biological Technology | 2,110 |
| CK Life Sciences Int'l., (Holdings) | 1,925 |
| Lepu Biopharma | 646 |
| Alphamab Oncology | 515 |
| Abbisko Cayman | 286 |
| Ascletis Pharma | 202 |
| CStone Pharmaceuticals | 102 |
| LongBio Pharma (Suzhou) | 94 |
CARsgen Therapeutics Holdings News
- 22 days ago - CARsgen Therapeutics Announces 2026 Interim Results - PRNewsWire
- 2 months ago - CARsgen Announces Approval of Satri-cel, the World's First CAR T-Cell Therapy Product for Solid Tumors - PRNewsWire
- 2 months ago - China approves CARsgen's CAR-T treatment to treat stomach cancer - Reuters
- 2 months ago - CARsgen Presents Allogeneic CAR T-cell Products CT0596 and CT1190B at EHA 2026 - PRNewsWire
- 3 months ago - Long-term Follow-up Results of CARsgen's Satri-cel as Sequential Therapy After First-Line Treatment for Gastric Cancer Presented at the 2026 ASCO Annual Meeting - PRNewsWire
- 6 months ago - CARsgen Therapeutics Announces 2025 Annual Results - PRNewsWire
- 6 months ago - CARsgen Signs Strategic Cooperation Agreements to Expand CAR-T Commercial Manufacturing Base in Jinshan, Shanghai - PRNewsWire
- 8 months ago - CARsgen and Dispatch Bio Announce Clinical Collaboration to Evaluate Flare Platform and Zevor-cel in Solid Tumors - PRNewsWire